Journal of Bioequivalence & Bioavailability

AZIDUS Laboratories Limited, Chennai, Tamil Nadu, India

Publications

• Research Article   
  Comparative Bioavailability Study of Rybelsus (Semaglutide) 3 mg Tablets of Novo Nordisk Versus Ozempic (Semaglutide) 2 mg/1.5 ml (1.34 mg/ml) Solution for Injection of Novo Nordisk under Fasting Condition in Healthy Subjects
  Author(s): Arjun Arumugam*, Geetha Lakshmi, Srinivas Gopineedu and Nageswara Rao
  
  Background: The human GLP-1 receptor agonist, semaglutide, functions by binding to albumin, which is facilitated by modifying position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. In this study, Novo Nordisk's Ozempic (Semaglutide/1.5 mL (1.34 mg/mL) solution for injection and Rybelsus (Semaglutide) 14 mg tablets) were compared to determine the pharmacokinetic parameters of Semaglutide after oral and subcutaneous administration in healthy subjects. Through the Flash Glucose Monitoring System with a sensor, we evaluated the pharmacodynamic response of semaglutide the absorption of glucose into the blood when the drug was administered in two different routes, using Novo Nordisk's Semaglutide 3 mg tablets in healthy subjects. To evaluate pharmacokinetics of Semaglutide injection and tablet and to assess the applicability of an LCMS/MS.. View more»
  

  DOI: 10.35248/0975-0851.24.16.606

  Abstract HTML PDF